SIMBLE SOLUTIONS LIMITED — Board/Management Information 2022

Feb 15, 2022

==> picture [596 x 141] intentionally omitted <==

----- Start of picture text -----

Simble Solutions Limited (ASX:SIS) | ASX Announcement
----- End of picture text -----

Dr Daniel Tillett Joins the Simble Board

16th February 2022

Sydney, 16 February 2022: Smart energy Software-as-a-Service (SaaS) company Simble Solutions Limited (ASX:SIS) (‘Simble’ or ‘the Company’) is pleased to announce that Dr Daniel Tillett has joined the Board of Directors in order to provide additional direction and leadership to the Company through its next stage of evolution.

Dr Tillett is the founder and CEO of Nucleics, a private Australian company producing and selling world leading DNA sequencing software to the genomics industry. Nucleics’ SAAS (software as a service) genomics tools are in use in more than 30 countries and at over 250 companies and institutions.

He is also Executive Director and Chief Scientific Officer of the ASX listed biotechnology company, Race Oncology (ASX:RAC). He joined the Race board in September 2019 and was instrumental in leading the strategic review and operational overhaul of Race that has grown its market capitalisation from less than $5 million in late 2019 to over $500 million by 2022. He is the largest shareholder in RAC having cornerstoned the August 2019 capital raising.

“We are delighted to have Daniel join the Board and are certain that he will make a great contribution to the Company. Outside of his commercial roles, Daniel is a prominent investor, who invested in Simble after doing his own substantial due diligence on our products and market potential. We welcome his expertise and interest in the work that Simble is doing to commercialise CarbonView and SimbleSense,” said SIS Chairman, Ben Loiterton.

“I look forward to working with the Simble team to drive a positive outcome for all shareholders,” said Dr Daniel Tillett. “The ESG sector is critical to Australia’s future, and I believe Simble can play a major role in our critical path to net zero.”

Dr Tillett owns 32.8 million SIS shares, representing 9.7% of issued shares. He owns an additional 14.9 million listed and unlisted SIS options.

Dr Tillett does not wish to receive board fees in cash and will instead be paid in options (subject to shareholder approval). He will receive 12 million options in the first year of his appointment, which will vest quarterly in arrears, at a strike price of $0.04 and expire 1 year from the date of appointment. Based on the above inputs, the value of the options is $37k using the Black-Scholes model.

The board believes that the near-term expiry date and strike price, which is 100% above the current share price of $0.02, will provide significant incentive for Dr Tillett to contribute to positive change at Simble, and that this is wholly aligned with the interests of shareholders. Dr Tillett’s remuneration will be reviewed by the board after 12 months.

Dr Tillett’s appointment is effective immediately.

1

Simble Solutions Limited, Level 2, 383 George Street, Sydney NSW 2000 P +61 2 8208 3366 E hello@simble.io ABN: 17 608 419 656

==> picture [596 x 141] intentionally omitted <==

----- Start of picture text -----

Simble Solutions Limited (ASX:SIS) | ASX Announcement
----- End of picture text -----

This announcement has been authorised by the Board of Simble Solutions Limited

About Dr Daniel Tillett

Dr Daniel Tillett is the founder and CEO of Nucleics, a private Australian biotechnology company producing and selling world leading DNA sequencing software to the Genomics industry. Nucleics SAAS (software as a service) genomics tools are in use in more than 30 countries and at over 250 companies and institutions. Dr Tillett has extensive commercial experience over the last 20 years in the biotech industry in project management, sales and marketing, IP management, fundraising and start-up investing.

Previously, he was a Senior Lecturer within the School of Pharmacy at La Trobe University where he taught and researched in the areas of pharmacy, phage therapy, microbiology, bioinformatics and cancer.

Dr Tillett has a PhD from the University of New South Wales in Molecular Genetics and Biochemistry. He has more than 40 scientific publications and granted patents in molecular biology, microbiology, genetics and biochemistry.

About Simble

Simble Solutions Limited (ASX:SIS) is a global software company focused on energy intelligence and business productivity Software-as-a-Service (SaaS) solutions.

The Simble Energy Business Unit includes the SimbleSense and CarbonView software platforms. SimbleSense is an integrated hardware and real-time software solution that enables businesses to visualise, control and monetise their energy systems. CarbonView is an enterprise grade Carbon and Sustainability Reporting platform that allows companies to measure and reduce their carbon emissions and meet their carbon reporting obligations.

Simble operates across all segments from Commercial & Industrial, through to Small to Medium Sized Enterprises (SME) and the residential market and targets the distribution of its platform through channel partners. Simble has an international presence with offices in Australia, the United Kingdom and Vietnam.

To learn more please visit: simblegroup.com

Investor & Corporate enquiries:

Ronen Ghosh

Chief Executive Officer Ph: +61 2 8208 3366 E: ronen@simble.io

2

Simble Solutions Limited, Level 2, 383 George Street, Sydney NSW 2000 P +61 2 8208 3366 E hello@simble.io ABN: 17 608 419 656